ClinicalTrials.gg
CompletedNCT01958827Updated Apr 12, 2016Results posted

A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease

A Phase 3 interventional study of Adalimumab in Crohn's Disease, sponsored by AbbVie. Completed. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2016-04-12.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
36th of 42
28 · median 143
Started
2013
with 2 others
Phase 3
22 of 42
none open now
Registered
23rd of 42
by date
Lead sponsor
6 of 42
AbbVie

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 36th largest by enrollment, is one of 3 that started in 2013, is one of 22 in phase 3, and was the 23rd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy, safety and pharmacokinetics after dose escalation in Japanese subjects with Crohn's Disease.

Read the detailed description

Subjects who are confirmed to meet all of the inclusion criteria and none of the exclusion criteria during screening period (≤ 21 days) will be given subcutaneous injections of open-label adalimumab 80 mg eow from Week 0 to Week 50. If a subject has an inadequate response at or after Week 8, the subject may be withdrawn from the study. Self-injection of study drug is permitted for the subjects who are willing to perform self-injection, if the investigator decided as appropriate. Disease activity will be evaluated by Crohn's disease activity index (CDAI) at Screening, Week 0 and every 4 weeks until Week 52. Follow-up will be performed at 70 days after the last dose of study drug by visit or telephone.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Dose Escalation
  • Crohn's Disease
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject ≥ 15 years of age at the time of .
  • Subject with Crohn's disease who received induction treatment of commercially available Humira® (160 mg initially and 80 mg at 2 weeks after initial dose), achieved response after initial dose, and then lost response during maintenance treatment with Humira®.
  • Subject with elevated C-reactive Protein (CRP) at Screening.
  • If female, subject is either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy) or is of childbearing potential and is practicing an approved method of throughout the study and for 150 days after the last dose of study drug.
  • Subject has a negative tuberculosis (TB) screening assessment. If the subject has evidence of a latent TB infection; the subject must initiate and complete a minimum of 21 days of an ongoing TB prophylaxis (in such case, screening period can be prolonged until 21 days past after initiation of prophylaxis and study drug is administered) or have documented completion of a full course of TB prophylaxis, prior to Week 0.

Exclusion criteria

Exclusion Criteria:

  • Subject with suspicion of colitis other than Crohn's disease.
  • Subject with an ostomy or ileoanal pouch. (Subjects with a previous ileo-rectal anastomosis are not excluded).
  • Subject with abscess or suspicion of abscess, or subject with infection(s).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Adalimumab 80 mg

    All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Adalimumab pre-filled syringe, administered by subcutaneous injection.

    Also known as: Humira, ABT-D2E7

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 8

    CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

    Time frame: Week 8

Secondary outcomes

  1. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Every 4 Weeks up to Week 52

    CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  2. Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) Every 4 Weeks up to Week 52

    CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used. Week 8 was the primary outcome measure.

    Time frame: Weeks 4, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  3. Percentage of Participants Who Achieved Clinical Response 70 (CR70; Crohn's Disease Activity Index [CDAI] Decrease ≥ 70 From Week 0) Every 4 Weeks up to Week 52

    CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  4. Percentage of Participants Who Achieved Clinical Response 100 (CR100; Crohn's Disease Activity Index [CDAI] Decrease of 100 From Week 0) Every 4 Weeks up to Week 52

    CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  5. C-reactive Protein (CRP): Mean Change From Baseline (Week 0) to Week 52

    C-reactive protein (CRP) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 0.3 mg/dL, slightly increasing with age. Last Observation Carried Forward (LOCF) was used for missing data.

    Time frame: Baseline (Week 0) and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  6. Number of Participants With Potentially Significant Hematology Parameters

    Blood was collected for analysis at designated study visits; hematology results were provided by each site laboratory. The number of participants with an abnormal laboratory result (higher than upper limit of normal \[ULN\] or lower than lower limit of normal \[LLN\]) meeting Common Toxicity Criteria (CTC) of Grade 3 or higher is summarized. Increase is signified by ↑. n=the number of participants with CTC Grade \<3 at baseline and a post-baseline value.

    Time frame: 52 weeks

  7. Number of Participants With Potentially Significant Clinical Chemistry Parameters

    Blood was collected for analysis at designated study visits; chemistry results were provided by a central laboratory. The number of participants with an abnormal laboratory result (higher than upper limit of normal \[ULN\] or lower than lower limit of normal \[LLN\]) meeting Common Toxicity Criteria (CTC) of Grade 3 or higher is summarized. n=the number of participants with CTC Grade \<3 at baseline and a post-baseline value for each parameter.

    Time frame: 52 weeks

  8. Systolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit

    Blood pressure was measured while the participant was sitting. n=the number of participants with available data at each time point.

    Time frame: Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  9. Diastolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit

    Blood pressure was measured while the participant was sitting. n=the number of participants with available data at each time point.

    Time frame: Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  10. Heart Rate: Mean Change From Baseline (Week 0) to Each Visit

    Heart rate was measured while the participant was sitting. n=the number of participants with available data at each time point.

    Time frame: Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  11. Body Temperature: Mean Change From Baseline (Week 0) to Each Visit

    n=the number of participants with available data at each time point.

    Time frame: Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52

  12. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs or TESAE) are defined as any event that began or worsened in severity after the first dose of study drug. The investigator assessed the relationship of each event to the use of study drug as either Reasonable possibility or No reasonable possibility of being related to study drug. For more details on adverse events please see the AE section below.

    Time frame: 60 weeks

Other outcomes

  1. Change in Mean Serum Adalimumab Concentration From Baseline (Week 0) to Week 52

    Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated heterogeneous electrochemiluminescence (ECL)-immunoassay method. The assay captures adalimumab via biotinylated anti-idiotypic antibody, and detects it via sulfo-tagged TNF-alpha. n=the number of participants with available data at each time point.

    Time frame: Baseline (Week 0) to Week 52

  2. Change in Number of Subjects Positive for Anti-Adalimumab Antibodies (AAA) From Baseline to Week 52

    Serum samples with adalimumab concentration below 2 μg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 20 ng/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose.

    Time frame: Baseline (Week 0) to Week 52

07

Results

Posted Apr 12, 2016

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab 80 mg
Started28
Completed18
Not completed10
Withdrew: Adverse event3
Withdrew: Lack of efficacy6
Withdrew: Concomitant prohibited medicine for ae1

Outcome measures

PrimaryPercentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 8

CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 8
percentage of participantsAdalimumab 80 mg
Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 875 (55.1 to 89.3)
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150) Every 4 Weeks up to Week 52

CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Every 4 Weeks up to Week 52
percentage of participantsAdalimumab 80 mg
Week 414.3 (4.0 to 32.7)
Week 825.0 (10.7 to 44.9)
Week 1228.6 (13.2 to 48.7)
Week 1632.1 (15.9 to 52.4)
Week 2035.7 (18.6 to 55.9)
Week 2442.9 (24.5 to 62.8)
Week 2835.7 (18.6 to 55.9)
Week 3242.9 (24.5 to 62.8)
Week 3639.3 (21.5 to 59.4)
Week 4039.3 (21.5 to 59.4)
Week 4442.9 (24.5 to 62.8)
Week 4839.3 (21.5 to 59.4)
Week 5235.7 (18.6 to 55.9)
SecondaryPercentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) Every 4 Weeks up to Week 52

CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used. Week 8 was the primary outcome measure.

Time frame:
Weeks 4, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) Every 4 Weeks up to Week 52
percentage of participantsAdalimumab 80 mg
Week 467.9 (47.6 to 84.1)
Week 1267.9 (47.6 to 84.1)
Week 1667.9 (47.6 to 84.1)
Week 2067.9 (47.6 to 84.1)
Week 2471.4 (51.3 to 86.8)
Week 2864.3 (44.1 to 81.4)
Week 3271.4 (51.3 to 86.8)
Week 3667.9 (47.6 to 84.1)
Week 4064.3 (44.1 to 81.4)
Week 4460.7 (40.6 to 78.5)
Week 4864.3 (44.1 to 81.4)
Week 5257.1 (37.2 to 75.5)
SecondaryPercentage of Participants Who Achieved Clinical Response 70 (CR70; Crohn's Disease Activity Index [CDAI] Decrease ≥ 70 From Week 0) Every 4 Weeks up to Week 52

CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response 70 (CR70; Crohn's Disease Activity Index [CDAI] Decrease ≥ 70 From Week 0) Every 4 Weeks up to Week 52
percentage of participantsAdalimumab 80 mg
Week 446.4 (27.5 to 66.1)
Week 857.1 (37.2 to 75.5)
Week 1264.3 (44.1 to 81.4)
Week 1664.3 (44.1 to 81.4)
Week 2064.3 (44.1 to 81.4)
Week 2467.9 (47.6 to 84.1)
Week 2864.3 (44.1 to 81.4)
Week 3267.9 (47.6 to 84.1)
Week 3664.3 (44.1 to 81.4)
Week 4060.7 (40.6 to 78.5)
Week 4457.1 (37.2 to 75.5)
Week 4860.7 (40.6 to 78.5)
Week 5257.1 (37.2 to 75.5)
SecondaryPercentage of Participants Who Achieved Clinical Response 100 (CR100; Crohn's Disease Activity Index [CDAI] Decrease of 100 From Week 0) Every 4 Weeks up to Week 52

CDAI is used to quantify the signs and symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Non-responder imputation (NRI) for missing CDAI observations was used.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response 100 (CR100; Crohn's Disease Activity Index [CDAI] Decrease of 100 From Week 0) Every 4 Weeks up to Week 52
percentage of participantsAdalimumab 80 mg
Week 432.1 (15.9 to 52.4)
Week 835.7 (18.6 to 55.9)
Week 1239.3 (21.5 to 59.4)
Week 1646.4 (27.5 to 66.1)
Week 2050.0 (30.6 to 69.4)
Week 2450.0 (30.6 to 69.4)
Week 2842.9 (24.5 to 62.8)
Week 3250.0 (30.6 to 69.4)
Week 3650.0 (30.6 to 69.4)
Week 4057.1 (37.2 to 75.5)
Week 4446.4 (27.5 to 66.1)
Week 4850.0 (30.6 to 69.4)
Week 5246.4 (27.5 to 66.1)
SecondaryC-reactive Protein (CRP): Mean Change From Baseline (Week 0) to Week 52

C-reactive protein (CRP) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Normal concentration in healthy human serum is usually lower than 0.3 mg/dL, slightly increasing with age. Last Observation Carried Forward (LOCF) was used for missing data.

Time frame:
Baseline (Week 0) and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · mg/dL
C-reactive Protein (CRP): Mean Change From Baseline (Week 0) to Week 52
mg/dLAdalimumab 80 mg
Week 4-0.570 ± 1.4902
Week 8-0.426 ± 1.6072
Week 12-0.710 ± 1.6769
Week 16-0.923 ± 1.6981
Week 20-0.907 ± 1.7532
Week 24-0.813 ± 1.7924
Week 28-0.833 ± 1.8820
Week 32-0.853 ± 2.0507
Week 36-0.586 ± 2.3271
Week 40-1.008 ± 2.0471
Week 44-0.915 ± 2.2324
Week 48-0.649 ± 2.5734
Week 52-0.570 ± 2.7635
Other pre-specifiedChange in Mean Serum Adalimumab Concentration From Baseline (Week 0) to Week 52

Blood samples were drawn prior to drug administration. Adalimumab concentrations in serum were determined using a validated heterogeneous electrochemiluminescence (ECL)-immunoassay method. The assay captures adalimumab via biotinylated anti-idiotypic antibody, and detects it via sulfo-tagged TNF-alpha. n=the number of participants with available data at each time point.

Time frame:
Baseline (Week 0) to Week 52
Reported as:
Mean · µg/mL
Change in Mean Serum Adalimumab Concentration From Baseline (Week 0) to Week 52
µg/mLAdalimumab 80 mg
Baseline (Week 0) (n=28)3.06 ± 2.19
Week 52 (n=18)9.47 ± 5.34
Other pre-specifiedChange in Number of Subjects Positive for Anti-Adalimumab Antibodies (AAA) From Baseline to Week 52

Serum samples with adalimumab concentration below 2 μg/mL were selected for AAA analyses. Samples were considered AAA positive if the measured AAA concentration was above 20 ng/mL. A subject was considered to be AAA positive if the subject had at least one AAA positive sample observed within 30 days following the subject's last adalimumab dose.

Time frame:
Baseline (Week 0) to Week 52
Reported as:
Number · participants
Change in Number of Subjects Positive for Anti-Adalimumab Antibodies (AAA) From Baseline to Week 52
participantsAdalimumab 80 mg
Baseline (Week 0)3
Week 524
SecondaryNumber of Participants With Potentially Significant Hematology Parameters

Blood was collected for analysis at designated study visits; hematology results were provided by each site laboratory. The number of participants with an abnormal laboratory result (higher than upper limit of normal \[ULN\] or lower than lower limit of normal \[LLN\]) meeting Common Toxicity Criteria (CTC) of Grade 3 or higher is summarized. Increase is signified by ↑. n=the number of participants with CTC Grade \<3 at baseline and a post-baseline value.

Time frame:
52 weeks
Reported as:
Number · participants
Number of Participants With Potentially Significant Hematology Parameters
participantsAdalimumab 80 mg
Haemoglobin <8 g/dL (n=27)1
Haemoglobin ↑ >4.0 g/dL (n=28)0
Platelet Count <5.0x10^4/mcL (n=28)0
White Blood Cells <2.0x10^3/mcL (n=28)0
Neutrophils <1.0x10^3/mcL(n=28)0
Lymphocytes <0.5x10^3/mcL (n=28)4
SecondaryNumber of Participants With Potentially Significant Clinical Chemistry Parameters

Blood was collected for analysis at designated study visits; chemistry results were provided by a central laboratory. The number of participants with an abnormal laboratory result (higher than upper limit of normal \[ULN\] or lower than lower limit of normal \[LLN\]) meeting Common Toxicity Criteria (CTC) of Grade 3 or higher is summarized. n=the number of participants with CTC Grade \<3 at baseline and a post-baseline value for each parameter.

Time frame:
52 weeks
Reported as:
Number · participants
Number of Participants With Potentially Significant Clinical Chemistry Parameters
participantsAdalimumab 80 mg
Alanine Aminotransferase >5xULN (n=28)0
Aspartate Aminotransferase >5xULN (n=28)0
Gamma-glutamyl Transpeptidase >5x ULN (n=28)0
Alkaline Phosphatase >5xU/L (n=28)0
Total Bilirubin >3xULN (n=28)0
Creatine Phosphokinase >5x ULN (n=28)1
Creatinine >3xULN or >3xBL (n=28)0
Uric Acid >10.0 mg/dL (n=28)0
Inorganic Phosphate <2.0 mg/dL (n=28)3
Calcium <7.0 mg/dL (n=28)1
Calcium >12.5 mg/dL (n=28)0
Sodium <130 mEq/L (n=28)0
Sodium >155 mEq/L (n=28)0
Potassium <3.0 mEq/L (n=27)0
Potassium >6.0 mEq/L (n=28)0
Non-fasting Glucose <40 mg/dL (n=28)0
Non-fasting Glucose >250 mg/dL (n=28)0
Albumin <2.0 g/dL (n=28)0
Cholesterol >400 mg/dL(n=28)0
Triglycerides >500 mg/dL(n=28)0
Magnesium <0.9 mg/dL (n=28)0
Magnesium >3.0 mg/dL (n=28)0
SecondarySystolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit

Blood pressure was measured while the participant was sitting. n=the number of participants with available data at each time point.

Time frame:
Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · mm Hg
Systolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit
mm HgAdalimumab 80 mg
Week 2 (n=28)-3.9 ± 11.98
Week 4 (n=28)-2.5 ± 9.41
Week 8 (n=25)-1.1 ± 9.98
Week 12 (n=21)-1.3 ± 9.34
Week 16 (n=21)-0.2 ± 11.72
Week 20 (n=20)1.9 ± 12.64
Week 24 (n=20)2.0 ± 8.89
Week 28 (n=20)0.8 ± 8.91
Week 32 (n=20)-1.7 ± 7.41
Week 36 (n=20)-0.5 ± 10.79
Week 40 (n=20)2.3 ± 9.55
Week 44 (n=19)1.9 ± 14.12
Week 48 (n=19)4.6 ± 11.66
Week 52 (n=18)-0.3 ± 9.41
SecondaryDiastolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit

Blood pressure was measured while the participant was sitting. n=the number of participants with available data at each time point.

Time frame:
Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · mm Hg
Diastolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit
mm HgAdalimumab 80 mg
Week 2 (n=28)-0.6 ± 9.53
Week 4 (n=28)0.2 ± 8.56
Week 8 (n=25)0.7 ± 8.13
Week 12 (n=21)1.1 ± 7.12
Week 16 (n=21)0.1 ± 7.78
Week 20 (n=20)0.8 ± 9.38
Week 24 (n=20)0.8 ± 8.72
Week 28 (n=20)-0.5 ± 7.81
Week 32 (n=20)-0.8 ± 9.27
Week 36 (n=20)-0.4 ± 10.27
Week 40 (n=20)0.7 ± 10.66
Week 44 (n=19)-1.2 ± 8.57
Week 48 (n=19)1.3 ± 8.48
Week 52 (n=18)3.0 ± 11.97
SecondaryHeart Rate: Mean Change From Baseline (Week 0) to Each Visit

Heart rate was measured while the participant was sitting. n=the number of participants with available data at each time point.

Time frame:
Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · bpm
Heart Rate: Mean Change From Baseline (Week 0) to Each Visit
bpmAdalimumab 80 mg
Week 2 (n=28)-0.3 ± 11.94
Week 4 (n=28)0.7 ± 12.78
Week 8 (n=25)-1.1 ± 9.48
Week 12 (n=21)-1.1 ± 11.59
Week 16 (n=21)-1.9 ± 9.56
Week 20 (n=20)-3.0 ± 8.68
Week 24 (n=20)-0.9 ± 13.15
Week 28 (n=20)-1.6 ± 11.30
Week 32 (n=20)-5.6 ± 11.95
Week 36 (n=20)-4.7 ± 12.88
Week 40 (n=20)-3.7 ± 13.88
Week 44 (n=19)-2.0 ± 10.78
Week 48 (n=19)-1.3 ± 15.53
Week 52 (n=18)-2.8 ± 11.80
SecondaryBody Temperature: Mean Change From Baseline (Week 0) to Each Visit

n=the number of participants with available data at each time point.

Time frame:
Baseline (Week 0) and Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Mean · degrees Celcius
Body Temperature: Mean Change From Baseline (Week 0) to Each Visit
degrees CelciusAdalimumab 80 mg
Week 2 (n=28)-0.03 ± 0.558
Week 4 (n=28)-0.02 ± 0.571
Week 8 (n=25)-0.08 ± 0.569
Week 12 (n=21)-0.14 ± 0.606
Week 16 (n=21)-0.11 ± 0.558
Week 20 (n=20)-0.16 ± 0.545
Week 24 (n=20)-0.20 ± 0.701
Week 28 (n=20)-0.23 ± 0.716
Week 32 (n=20)-0.26 ± 0.762
Week 36 (n=20)-0.36 ± 0.476
Week 40 (n=20)-0.16 ± 0.555
Week 44 (n=19)-0.24 ± 0.472
Week 48 (n=19)-0.03 ± 0.781
Week 52 (n=18)-0.13 ± 0.717
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs or TESAE) are defined as any event that began or worsened in severity after the first dose of study drug. The investigator assessed the relationship of each event to the use of study drug as either Reasonable possibility or No reasonable possibility of being related to study drug. For more details on adverse events please see the AE section below.

Time frame:
60 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsAdalimumab 80 mg
Any TEAE24
TEAEs with reasonable possibility of being related5
Any severe TEAE2
TESAE8
Any TEAE Leading to Discontinuation of Study4
Death0

Adverse events

Collected over AEs were collected from the time of study drug administration until 70 days after last dose of study drug (60 weeks); SAEs were also collected from the time that informed consent was obtained until 70 days after last dose of study drug (up to 63 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab 80 mg—8/28 (28.6%)21/28 (75%)
Most frequent serious events
Most frequent serious events
EventAdalimumab 80 mg
CROHN'S DISEASEGastrointestinal disorders4/28
ILEUSGastrointestinal disorders1/28
INTESTINAL OBSTRUCTIONGastrointestinal disorders1/28
SMALL INTESTINAL ULCER HAEMORRHAGEGastrointestinal disorders1/28
SUBILEUSGastrointestinal disorders1/28
ANAL ABSCESSInfections and infestations1/28
PNEUMONIA BACTERIALInfections and infestations1/28
ALLERGIC TRANSFUSION REACTIONInjury, poisoning and procedural complications1/28
Most frequent other events
Showing 10 of 45
Most frequent other events
EventAdalimumab 80 mg
NASOPHARYNGITISInfections and infestations13/28
RASHSkin and subcutaneous tissue disorders4/28
HEADACHENervous system disorders3/28
ANAEMIABlood and lymphatic system disorders2/28
ABDOMINAL DISTENSIONGastrointestinal disorders2/28
NAUSEAGastrointestinal disorders2/28
PYREXIAGeneral disorders2/28
BRONCHITISInfections and infestations2/28
INFLUENZAInfections and infestations2/28
OTITIS EXTERNAInfections and infestations2/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Adalimumab 80 mg
Mean33.6 ± 10.09
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 80 mg
Female12
Male16
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Motoya S, Watanabe M, Wallace K, Lazar A, Nishimura Y, Ozawa M, Thakkar R, Robinson AM, Singh RSP, Mostafa NM, Suzuki Y, Hibi T. Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. Inflamm Intest Dis. 2018 Jul;2(4):228-235. doi: 10.1159/000486786. Epub 2018 May 15. PubMed 30221150 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Mar 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2013
First posted
Oct 9, 2013
Start
Sep 2013
Primary completionActual
Mar 2015
CompletionActual
Oct 2015
Results first posted
Apr 12, 2016
Last update
Apr 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01958827
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 9, 2013
Start date
Sep 2013
Primary completion
Mar 2015
Completion
Oct 2015
Results posted
Apr 12, 2016
Last update
Apr 12, 2016

Study contacts

Morio Ozawa, MS
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion